WO2008139170A3 - Agents améliorant l'administration transdermique et transmucosale de médicament - Google Patents

Agents améliorant l'administration transdermique et transmucosale de médicament Download PDF

Info

Publication number
WO2008139170A3
WO2008139170A3 PCT/GB2008/001627 GB2008001627W WO2008139170A3 WO 2008139170 A3 WO2008139170 A3 WO 2008139170A3 GB 2008001627 W GB2008001627 W GB 2008001627W WO 2008139170 A3 WO2008139170 A3 WO 2008139170A3
Authority
WO
WIPO (PCT)
Prior art keywords
transdermal
drug delivery
formula
transmucosal drug
delivery enhancers
Prior art date
Application number
PCT/GB2008/001627
Other languages
English (en)
Other versions
WO2008139170A2 (fr
Inventor
Ola Chamber
Brent Thelin
Original Assignee
Sinclair Pharmaceuticals Ltd
Ola Chamber
Brent Thelin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinclair Pharmaceuticals Ltd, Ola Chamber, Brent Thelin filed Critical Sinclair Pharmaceuticals Ltd
Priority to ES08750563T priority Critical patent/ES2744864T3/es
Priority to EP08750563.2A priority patent/EP2167056B1/fr
Publication of WO2008139170A2 publication Critical patent/WO2008139170A2/fr
Publication of WO2008139170A3 publication Critical patent/WO2008139170A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Abstract

L'invention concerne des composés de la formule (I) dont on a trouvé qu'ils sont des agents efficaces améliorant la pénétration transdermique et transmucosale. Une composition de l'invention comprend par conséquent un composé de la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci et un agent pharmacologiquement actif, dans lequel: X est O ou CH-R5, R5 est un alkyle en C5-C14 ramifié ou droit, notamment le 2-propylpentyle; et lorsque X est O, alors R1, R2, R3 et R4 sont chacun indépendamment H ou au mieux deux d'entre eux sont un alkyle en C4-C16 ramifié ou droit, le reste étant H, A est (CH2)2-6, R6 est OH; et lorsque X est CH-R5, alors R1, R2, R3 et R4 sont H ; A est (CH)2-6 ou CO(CH2)6-14; R6 est CH3 ou OH; et N dans la formule (I) étant facultativement quaternisé, comprenant des formes racémiques et énantiomères.
PCT/GB2008/001627 2007-05-09 2008-05-09 Agents améliorant l'administration transdermique et transmucosale de médicament WO2008139170A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES08750563T ES2744864T3 (es) 2007-05-09 2008-05-09 Agentes potenciadores de la administración transdérmica y transmucosa de fármacos
EP08750563.2A EP2167056B1 (fr) 2007-05-09 2008-05-09 Agents améliorant l'administration transdermique et transmucosale de médicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708960.0A GB0708960D0 (en) 2007-05-09 2007-05-09 Method
GB0708960.0 2007-05-09

Publications (2)

Publication Number Publication Date
WO2008139170A2 WO2008139170A2 (fr) 2008-11-20
WO2008139170A3 true WO2008139170A3 (fr) 2009-07-23

Family

ID=38219137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/001627 WO2008139170A2 (fr) 2007-05-09 2008-05-09 Agents améliorant l'administration transdermique et transmucosale de médicament

Country Status (4)

Country Link
EP (1) EP2167056B1 (fr)
ES (1) ES2744864T3 (fr)
GB (1) GB0708960D0 (fr)
WO (1) WO2008139170A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502046D0 (en) 2005-02-01 2005-03-09 Sinclair Pharmaceuticals Ltd Method
GB0714338D0 (en) * 2007-07-23 2007-09-05 Sinclair Pharmaceuticals Ltd method
WO2015095644A1 (fr) 2013-12-20 2015-06-25 AntiOP, Inc. Compositions de naloxone intranasales et leurs procédés de préparation et d'utilisation
US11723864B2 (en) 2015-05-29 2023-08-15 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
IT201600130538A1 (it) * 2016-12-23 2018-06-23 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione del delmopinolo
IT201600130642A1 (it) * 2016-12-23 2018-06-23 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione di 2(3 alchilmorfolino)-etan-1-olo
IT201600130729A1 (it) 2016-12-23 2018-06-23 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione degli intermedi del delmopinolo

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268222A2 (fr) * 1986-11-19 1988-05-25 Research Triangle Pharmaceuticals Ltd. Agents améliorant la pénétration pour la délivrance transdermale de médicaments systémiques
WO1998011222A1 (fr) * 1996-09-13 1998-03-19 The Mount Sinai School Of Medicine Of The City University Of New York Methodes de selection de composes utilisables pour traiter la schizophrenie
WO2007010294A2 (fr) * 2005-07-22 2007-01-25 Sinclair Pharmaceuticals Limited Traitement de l'acne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268222A2 (fr) * 1986-11-19 1988-05-25 Research Triangle Pharmaceuticals Ltd. Agents améliorant la pénétration pour la délivrance transdermale de médicaments systémiques
WO1998011222A1 (fr) * 1996-09-13 1998-03-19 The Mount Sinai School Of Medicine Of The City University Of New York Methodes de selection de composes utilisables pour traiter la schizophrenie
WO2007010294A2 (fr) * 2005-07-22 2007-01-25 Sinclair Pharmaceuticals Limited Traitement de l'acne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEALY N ET AL: "Delmopinol hydrochloride. Dental plaque formation inhibitor, treatment of gingivitis", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 21, no. 8, 1 January 1996 (1996-01-01), pages 787 - 791, XP009080745, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
EP2167056B1 (fr) 2019-05-01
WO2008139170A2 (fr) 2008-11-20
GB0708960D0 (en) 2007-06-20
EP2167056A2 (fr) 2010-03-31
ES2744864T3 (es) 2020-02-26

Similar Documents

Publication Publication Date Title
WO2008139170A3 (fr) Agents améliorant l'administration transdermique et transmucosale de médicament
WO2010136474A3 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
JO3598B1 (ar) الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
PH12016502175A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
EP2660241A3 (fr) Composés stéroïdiques comprenant un c-17-hétéroaryle en tant qu'inhibiteurs de cyp11-b, cyp17, et/ou cyp21
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
WO2010011821A3 (fr) Agents anti-hypertensifs à double action
JP2012520342A5 (fr)
MY151295A (en) Pyrimidyl indoline compound
PE20081596A1 (es) Derivados fluorinados de deferiprona
TW200602035A (en) [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
UA96753C2 (ru) Лекарственное средство, которое содержит фторхинолоны
EP2077846A4 (fr) Composés de benzoxazépine, leur préparation et leur utilisation
WO2009038412A3 (fr) Composés inhibiteurs de la béta-sécrétase
WO2009145591A3 (fr) Composés de phényl-pipérazine, composition pharmaceutique les comprenant, et utilisation associée
WO2008092072A3 (fr) Modulateurs du récepteur métabotropique du glutamate de sous-type 5 et leurs utilisations
WO2006079077A3 (fr) Composes en tant que modulateurs de recepteur de ghreline et leurs utilisations
ATE408610T1 (de) Alkyl-und piperidin-substitutierte benzimidazol- derivate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750563

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008750563

Country of ref document: EP